New cancer drug trial seeks to control advanced tumors
NCT ID NCT05518045
Summary
This study is testing LM-108, a new antibody drug, in patients with advanced solid tumors that have stopped responding to standard treatments. Researchers will give LM-108 either alone or combined with other cancer therapies to 392 participants to check safety and see if it helps control tumor growth. The trial aims to find the right dose and gather early evidence about whether this approach can help patients who have run out of treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.